Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Why Micropolis Holding Co. (NYSE American: MCRP) Is ‘One to Watch’
Micropolis (NYSE American: MCRP) is a robotics and AI technology company pioneering the development of unmanned…
-
QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Positioned in North America’s Critical Minerals Future
Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) was featured in a recent article that discusses the…
-
QualityStocksNewsBreaks – Copper’s Moment: Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Taps Rising Demand with BC Projects and Custom Mill
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF), a junior exploration and custom milling company, is poised…